{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:09:49Z","timestamp":1744178989824},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","medical.theclinics.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.mcna.2016.03.005","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T04:42:41Z","timestamp":1464237761000},"page":"665-693","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Update in Hypertension Therapy"],"prefix":"10.1016","volume":"100","author":[{"given":"Leonard A.","family":"Mankin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2016.03.005_bib1","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A\u00a0comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2016.03.005_bib2","first-page":"1","article-title":"Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012","volume":"133","author":"Nwankwo","year":"2013","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.mcna.2016.03.005_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)70151-3","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2016.03.005_bib4","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/CIRCULATIONAHA.108.191261","article-title":"Heart disease and stroke statistics\u20132009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"119","author":"Lloyd-Jones","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2016.03.005_bib5","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2016.03.005_bib6","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2016.03.005_bib7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jama.1997.03540330061036","article-title":"Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis","volume":"277","author":"Psaty","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2016.03.005_bib8","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.mcna.2016.03.005_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004349.pub2","article-title":"Treatment blood pressure targets for hypertension","author":"Arguedas","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2016.03.005_bib10","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"Appel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2016.03.005_bib13","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib14","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib15","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group","volume":"265","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2016.03.005_bib16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet"},{"issue":"10017","key":"10.1016\/j.mcna.2016.03.005_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0140-6736(15)00816-8","article-title":"Lower blood pressure targets: to whom do they apply?","volume":"387","author":"Brunstr\u00f6m","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.mcna.2016.03.005_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/M13-2981","article-title":"Evidence supporting a systolic blood pressure goal of less than 150\u00a0mm Hg in patients aged 60 years or older: the minority view","volume":"160","author":"Wright","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib19","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.2011.1821","article-title":"Association between chlorthalidone treatment of systolic hypertension and long-term survival","volume":"306","author":"Kostis","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2016.03.005_bib20","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/archinternmed.2009.60","article-title":"ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses","volume":"169","author":"Wright","year":"2009","journal-title":"Arch Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2016.03.005_bib21","first-page":"S1","article-title":"Standards of medical care in diabetes\u20132015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"issue":"16","key":"10.1016\/j.mcna.2016.03.005_bib22","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mcna.2016.03.005_bib23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1161\/01.HYP.0000231662.77359.de","article-title":"Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial","volume":"48","author":"Leenen","year":"2006","journal-title":"Hypertension"},{"issue":"19","key":"10.1016\/j.mcna.2016.03.005_bib24","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2016.03.005_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","article-title":"Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis","volume":"55","author":"Gupta","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.mcna.2016.03.005_bib27","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1185\/03007995.2010.494462","article-title":"Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives","volume":"26","author":"Yang","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mcna.2016.03.005_bib28","first-page":"108","article-title":"Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States","volume":"14","author":"Aagren","year":"2011","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.mcna.2016.03.005_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jash.2010.02.005","article-title":"Combination therapy in hypertension","volume":"4","author":"Gradman","year":"2010","journal-title":"J\u00a0Am Soc Hypertens"},{"issue":"7","key":"10.1016\/j.mcna.2016.03.005_bib30","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1097\/HJH.0b013e328339f9fa","article-title":"Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice","volume":"28","author":"Corrao","year":"2010","journal-title":"J\u00a0Hypertens"},{"issue":"4","key":"10.1016\/j.mcna.2016.03.005_bib31","first-page":"S14","article-title":"Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease","volume":"137","author":"Smolensky","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/IBPC.S4364","article-title":"Can nocturnal hypertension predict cardiovascular risk?","volume":"2","author":"Friedman","year":"2009","journal-title":"Integr Blood Press Control"},{"issue":"1","key":"10.1016\/j.mcna.2016.03.005_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/HYPERTENSIONAHA.107.100727","article-title":"Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension","volume":"51","author":"Fagard","year":"2008","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.mcna.2016.03.005_bib34","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/dc11-0297","article-title":"Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes","volume":"34","author":"Hermida","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2016.03.005_bib35","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1681\/ASN.2011040361","article-title":"Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD","volume":"22","author":"Hermida","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2016.03.005_bib36","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes\u20132013","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.mcna.2016.03.005_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009096.pub2","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"10.1016\/j.mcna.2016.03.005_bib38","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.mcna.2016.03.005_bib39","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib40","series-title":"2015\u00a0USRDS annual data report: Epidemiology of kidney disease in the United States","author":"United States Renal Data System","year":"2015"},{"key":"10.1016\/j.mcna.2016.03.005_bib41","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.mcna.2016.03.005_bib42","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib46","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2016.03.005_bib49","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A\u00a0randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"9386","key":"10.1016\/j.mcna.2016.03.005_bib50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2016.03.005_bib51","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib52","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib53","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mcna.2016.03.005_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008169.pub2","article-title":"Spironolactone for hypertension","author":"Batterink","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2016.03.005_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/jhh.2014.64","article-title":"Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis","volume":"29","author":"Liu","year":"2015","journal-title":"J\u00a0Hum Hypertens"},{"issue":"13","key":"10.1016\/j.mcna.2016.03.005_bib56","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/CIRCULATIONAHA.112.097345","article-title":"Resistant hypertension: incidence, prevalence, and prognosis","volume":"125","author":"Pimenta","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2016.03.005_bib57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension","volume":"55","author":"de Souza","year":"2010","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.mcna.2016.03.005_bib58","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.mcna.2016.03.005_bib59","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/B:CARD.0000015855.02485.e3","article-title":"Cardiovascular drugs and serum uric acid","volume":"17","author":"Reyes","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.mcna.2016.03.005_bib60","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/00004872-199507001-00003","article-title":"Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects","volume":"13","author":"Burnier","year":"1995","journal-title":"J\u00a0Hypertens Suppl"},{"key":"10.1016\/j.mcna.2016.03.005_bib61","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1097\/HJH.0b013e3281c49d93","article-title":"Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome","volume":"25","author":"Ruilope","year":"2007","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.mcna.2016.03.005_bib62","doi-asserted-by":"crossref","first-page":"d8190","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study","volume":"344","author":"Choi","year":"2012","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.mcna.2016.03.005_bib63","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","article-title":"Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors","volume":"8","author":"Oliva","year":"2014","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.mcna.2016.03.005_bib64","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J\u00a0Am Soc Hypertens"},{"issue":"1","key":"10.1016\/j.mcna.2016.03.005_bib65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jash.2014.11.001","article-title":"SGLT2 inhibitors: their potential reduction in blood pressure","volume":"9","author":"Maliha","year":"2015","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.mcna.2016.03.005_bib66","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib67","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamainternmed.2013.14547","article-title":"Vegetarian diets and blood pressure: a meta-analysis","volume":"174","author":"Yokoyama","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.mcna.2016.03.005_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008893.pub2","article-title":"Effect of cocoa on blood pressure","author":"Ried","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mcna.2016.03.005_bib69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1741-7015-8-39","article-title":"Does chocolate reduce blood pressure? A meta-analysis","volume":"8","author":"Ried","year":"2010","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.mcna.2016.03.005_bib70","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1017\/S0007114514001731","article-title":"Effects of tea intake on blood pressure: a meta-analysis of randomised controlled trials","volume":"112","author":"Liu","year":"2014","journal-title":"Br J Nut"},{"issue":"4","key":"10.1016\/j.mcna.2016.03.005_bib71","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3945\/ajcn.111.016667","article-title":"The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis","volume":"94","author":"Mesas","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.mcna.2016.03.005_bib72","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.HYP.33.2.647","article-title":"The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials","volume":"33","author":"Jee","year":"1999","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.mcna.2016.03.005_bib73","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2147\/VHRM.S3055","article-title":"Habitual coffee consumption and blood pressure: an epidemiological perspective","volume":"4","author":"Geleijnse","year":"2008","journal-title":"Vasc Health Risk Manag"},{"issue":"3","key":"10.1016\/j.mcna.2016.03.005_bib74","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/jhh.2014.52","article-title":"Massage therapy for essential hypertension: a systematic review","volume":"29","author":"Xiong","year":"2015","journal-title":"J\u00a0Hum Hypertens"},{"issue":"2","key":"10.1016\/j.mcna.2016.03.005_bib75","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1751-7141.2008.07565.x","article-title":"The effect of tai chi exercise on blood pressure: a systematic review","volume":"11","author":"Yeh","year":"2008","journal-title":"Prev Cardiol"},{"issue":"7","key":"10.1016\/j.mcna.2016.03.005_bib76","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.amjcard.2015.07.012","article-title":"Community-based mind-body meditative tai chi program and its effects on improvement of blood pressure, weight, renal function, serum lipoprotein, and quality of life in Chinese Adults with hypertension","volume":"116","author":"Sun","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.mcna.2016.03.005_bib77","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study","volume":"373","author":"Krum","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2016.03.005_bib78","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial","volume":"376","author":"Esler","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2016.03.005_bib79","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A\u00a0controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2016.03.005_bib80","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/HYPERTENSIONAHA.109.140665","article-title":"Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients","volume":"55","author":"Heusser","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.mcna.2016.03.005_bib81","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial","volume":"58","author":"Bisognano","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712516000353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712516000353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T18:53:54Z","timestamp":1536692034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712516000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0025712516000353"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2016.03.005","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update in Hypertension Therapy","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2016.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}